本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、监事会会议召开情况 成都普瑞眼科医院集团股份有限公司（以下简称"公司"）第三届监事会 第十九次会议通知于2024年10月25日以书面、电子邮件的方式向全体监事发出 并送达，会议于2024年10月29日以现场结合通讯方式召开。本次会议应出席监 事3人，实际出席监事3人。会议由监事会主席雷德芳女士主持。本次会议的召 集、召开和表决程序符合《中华人民共和国公司法》等法律、法规、规范性文 件以及《公司章程》的有关规定。 二、监事会会议审议情况 经与会监事认真审议，表决了以下议案： （一）审议通过《关于公司<2024年第三季度报告>的议案》 经审议，监事会认为：公司《2024年第三季度报告》的编制和审议程序符 合法律、行政法规、中国证监会和深圳证券交易所的规定，报告内容真实、准 确、完整地反映了公司的经营情况，不存在虚假记载、误导性陈述或者重大遗 漏。 具体内容详见同日在巨潮资讯网（www.cninfo.com.cn）披露的《2024年第 三季度报告》。 证券代码：301239 证券简称：普瑞眼科 公告编号：2024- ...

第三届董事会第二十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 证券代码：301239 证券简称：普瑞眼科 公告编号：2024-056 成都普瑞眼科医院集团股份有限公司 具体内容详见同日在巨潮资讯网（www.cninfo.com.cn）披露的《2024年第 三季度报告》。 本议案已经第三届董事会审计委员会审议通过。 表决情况：同意7票，反对0票，弃权0票。 三、备查文件 1．公司第三届董事会第二十五次会议决议； 2．公司第三届董事会审计委员会第九次会议决议。 一、董事会会议召开情况 成都普瑞眼科医院集团股份有限公司（以下简称"公司"）第三届董事会 第二十五次会议通知于2024年10月25日以书面、电子邮件的方式向全体董事发 出并送达，会议于2024年10月29日以现场结合通讯方式召开。本次会议应出席 董事7人，实际出席董事7人。会议由董事长徐旭阳先生主持，公司全体监事和 高级管理人员列席会议。本次会议的召集、召开和表决程序符合《中华人民共 和国公司法》等法律、法规、规范性文件以及《公司章程》的有关规定。 二、董事会会议审议情况 经与会董事认 ...

Financial Performance - The company's operating revenue for Q3 2024 was ¥716,338,343.26, a decrease of 9.11% compared to the same period last year[2] - The net profit attributable to shareholders was -¥27,453,286.21, representing a decline of 133.31% year-on-year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥27,004,706.62, down 133.17% from the previous year[2] - Total operating revenue for Q3 2024 was CNY 2,136,699,863.80, a decrease of 1.36% compared to CNY 2,166,125,568.45 in Q3 2023[15] - Net profit for Q3 2024 was CNY 50,835,668.99, down 35.06% from CNY 78,428,960.14 in Q3 2023[16] - The net profit attributable to shareholders of the parent company for Q3 2024 is CNY 15,841,198.32, compared to CNY 317,242,547.43 in the same period last year[17] - The total comprehensive income for Q3 2024 is CNY 22,845,948.88, with CNY 15,841,198.32 attributable to the parent company[17] - The basic and diluted earnings per share for Q3 2024 are both CNY 0.11, down from CNY 2.12 in the previous year[17] Assets and Liabilities - The total assets at the end of Q3 2024 were ¥4,705,861,156.23, a decrease of 2.27% from the end of the previous year[2] - The company's total assets decreased to CNY 4,705,861,156.23 from CNY 4,815,000,387.93, a decline of 2.28%[15] - Current liabilities totaled CNY 785,182,561.51, down from CNY 1,043,136,742.01, a decrease of 24.73%[15] - Long-term borrowings increased significantly to CNY 364,552,603.84 from CNY 94,806,722.63, representing a growth of 284.56%[15] - The total equity attributable to shareholders decreased by 3.21% to ¥2,218,116,822.82 compared to the end of the previous year[2] - The total equity attributable to shareholders decreased to CNY 2,218,116,822.82 from CNY 2,291,622,601.45, a decline of 3.19%[15] Cash Flow - Cash flow from operating activities for the year-to-date was ¥414,469,212.80, down 24.40% year-on-year[2] - Cash flow from operating activities for Q3 2024 is CNY 414,469,212.80, a decrease from CNY 548,228,797.85 in the same period last year[19] - Cash inflow from operating activities totals CNY 2,184,953,764.81, while cash outflow totals CNY 1,770,484,552.01[19] - Cash flow from investing activities shows a net outflow of CNY 613,278,600.03, compared to a net outflow of CNY 362,555,474.05 in the previous year[19] - Cash flow from financing activities results in a net outflow of CNY 126,944,951.80, compared to a net outflow of CNY 54,728,712.51 last year[19] - The net increase in cash and cash equivalents for Q3 2024 is CNY -325,754,339.03, compared to an increase of CNY 130,944,611.29 in the same period last year[20] - The ending balance of cash and cash equivalents is CNY 479,822,198.29, down from CNY 1,057,174,443.01 in the previous year[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 11,413[7] - Chengdu Puri Century Investment Co., Ltd. holds 35.91% of shares, totaling 53,729,585 shares, with 14,330,000 shares pledged[7] - Xu Xuyang, a natural person shareholder, holds 6.75% of shares, totaling 10,100,000 shares, with 7,000,000 shares pledged[7] - The top ten shareholders include entities such as Fushui Zhengxin Investment Partnership and Fushui Jinguang Qingcheng Investment Partnership, holding 4.01% and 3.11% respectively[7] - The top ten shareholders do not participate in margin financing or securities lending activities[11] - The company has not identified any other shareholders with related party relationships or acting in concert[11] - The company has not disclosed any other significant matters related to shareholders or shareholding changes[11] Operational Costs and Expenses - The company reported a significant increase in financial expenses by 34.05% to ¥61,638,478.21 due to new hospital leases[6] - Investment income dropped by 98.60% to ¥1,293,828.40, primarily due to the previous year's merger-related gains[6] - The company experienced a 34.30% increase in taxes and surcharges, totaling ¥5,579,082.07, mainly due to new property taxes[5] - Total operating costs amounted to CNY 2,058,379,113.42, up from CNY 1,846,235,666.59 in the previous year, reflecting an increase of 11.45%[16] - Research and development expenses for Q3 2024 were CNY 4,878,194.72, a decrease of 31.83% compared to CNY 7,155,122.27 in Q3 2023[16] Inventory and Receivables - The company reported a decrease in accounts receivable to CNY 100,681,983.67 from CNY 119,291,063.08, a reduction of 15.59%[15] - Inventory increased to CNY 162,949,240.82 from CNY 151,526,659.11, an increase of 7.93%[15] Audit and Reporting - The company has not undergone an audit for the Q3 2024 report[20] - The report indicates no changes in the number of restricted shares during the period[13] - The company has not reported any new strategies or significant developments in product or technology during this quarter[11]

证券代码：301239 证券简称：普瑞眼科 公告编号：2024-055 成都普瑞眼科医院集团股份有限公司 关于控股股东、实际控制人部分股份质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 | | | 质 | 押 | 用 | 途 | | | | | 补 | 充 | 质 | 押 | | | | | | 补 | 充 | 质 | 押 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 质权 | 人 | | | | | | 中原 | 信托 | 有限 | 公司 | | | | | | 云南 | 国际 | 信托 | 有限 | 公司 | | | 质 | 押 | 到 | | 期 | 日 | | | | 办 | 理 | 解 | 除 | 质 | 押 | 手 | 续 | 止 | 办 | 理 | 解 | 除 | 质 ...

| 保荐机构名称：海通证券股份有限公司 | 被保荐公司简称：普瑞眼科 | | --- | --- | | 保荐代表人姓名：田卓玲 | 联系电话：021-23219000 | | 保荐代表人姓名：朱玉峰 | 联系电话：021-23219000 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 无 | | 2．督导公司建立健全并有效执行规章制度的 | | | 情况 | | | （1）是否督导公司建立健全规章制度（包括 | | | 但不限于防止关联方占用公司资源的制度、 | 是 | | 募集资金管理制度、内控制度、内部审计制 | | | 度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 6 次 | | （2）公司募集资金项目进展是否与信息披露 | 是 | | 文件一致 | | | 4.公司治理督导情况 | | | （1）列席公司股东大会次数 | 0 ...

北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于成都普瑞眼科医院集团股份有限公司 2024 年第二次临时股东大会的 法律意见书 国枫律股字[2024]A0456 号 致：成都普瑞眼科医院集团股份有限公司（贵公司） 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出席并见 证贵公司 2024 年第二次临时股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东大会规则》（以下简 称"《股东大会规则》"）、《律师事务所从事证券法律业务管理办法》（以下简称"《证券 法律业务管理办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简称"《证 券法律业务执业规则》"）等相关法律、行政法规、规章、规范性文件及《成都普瑞眼科 医院集团股份有限公司章程》（以下简称"《公司章程》"）的规定，就本次会议的召集与 召开程序、召集人资格、出席会议人员资格、会议表决 ...

证券代码：301239 证券简称：普瑞眼科 公告编号：2024-054 成都普瑞眼科医院集团股份有限公司 2024年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1．本次股东大会不存在否决议案的情形； 2．本次股东大会不涉及变更以往股东大会已通过的决议。 （一）会议召开情况 1．会议召开时间 （1）现场会议时间：2024年9月10日（星期二）15:30； （2）网络投票时间 其中，通过深圳证券交易所交易系统进行网络投票的时间为：2024年9月10 日上午9:15-9:25、9:30-11:30，下午13:00-15:00；通过深圳证券交易所互联 网投票系统进行网络投票的时间为：2024年9月10日9:15-15:00。 2．现场会议召开地点：上海市长宁区茅台路899号6楼会议室。 3．会议召开的方式：本次股东大会采用现场投票与网络投票相结合的方式 召开。 4．会议召集人：成都普瑞眼科医院集团股份有限公司（以下简称"公司"） 董事会。 5．会议主持人：公司董事长徐旭阳先生。 6．本次股东大会的召集和召开符合有关法律、法规 ...

Investment Rating - The report maintains a "Recommended" investment rating for the company with a target price of 45 yuan [1]. Core Insights - The company's mid-year report for 2024 met expectations, showing a revenue of 1.42 billion yuan (+3.08%) and a net profit attributable to shareholders of 43 million yuan (-81.56%) [1]. - The company is experiencing a strategic shift towards expanding its cataract and comprehensive eye disease services, with significant growth in cataract revenue [2]. - The company has established over 30 specialized eye hospitals and clinics, with strong performance from core self-built hospitals and robust growth from acquisitions [2]. - Revenue forecasts for 2024-2026 have been adjusted to 3.136 billion, 3.667 billion, and 4.289 billion yuan, reflecting a year-on-year growth of 15.4%, 16.9%, and 17.0% respectively [2]. Financial Performance Summary - Total revenue for 2023 was 2.718 billion yuan, with a projected revenue of 3.136 billion yuan for 2024, reflecting a growth rate of 15.4% [3]. - The net profit attributable to shareholders for 2023 was 268 million yuan, with a forecasted decline to 169 million yuan in 2024, followed by a recovery to 217 million yuan in 2025 and 261 million yuan in 2026 [3]. - Earnings per share (EPS) is projected to be 1.13 yuan in 2024, with a price-to-earnings (P/E) ratio of 28 [3].

Investment Rating - The report maintains a "Buy" rating for the company [4] Core Views - The company's performance is under short-term pressure, but the cataract and eye disease segments are experiencing growth, supporting future expansion [2] - With improvements in the consumer environment and new hospitals moving past their cultivation period, revenue is expected to rebound [2] Summary by Sections Financial Performance - For H1 2024, the company achieved revenue of 1.42 billion yuan, a 3.08% increase, but net profit attributable to shareholders dropped by 81.56% to 43 million yuan [3] - Q2 2024 revenue was 745 million yuan, up 2.24%, with net profit down 63.59% to 26 million yuan [3] - H1 gross margin was 41.29%, down 4.09 percentage points, and net margin was 3.37%, down 14.08 percentage points, primarily due to revenue pressure and costs associated with new hospital operations [3] Business Segments - The company is optimizing its business structure to avoid over-reliance on refractive surgery revenue, with refractive income at 692 million yuan, down 2.50% [3] - Cataract revenue increased by 13.22% to 311 million yuan, while comprehensive eye disease revenue rose by 14.87% to 226 million yuan [3] Expansion Strategy - The company is advancing its expansion strategy with a focus on "national chain + regional integration," having opened six new hospitals in H1 2024 [3] - As of H1 2024, the company has established 33 specialized eye hospitals across over 20 municipalities and provincial capitals, with more in the pipeline [3] Valuation - The target price is adjusted to 43.03 yuan, based on a 2024 price-to-sales ratio of 2.24x, reflecting a lower valuation compared to industry peers [3][12]

证券代码：301239 证券简称：普瑞眼科 公告编号：2024-048 成都普瑞眼科医院集团股份有限公司 第三届董事会第二十四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 成都普瑞眼科医院集团股份有限公司（以下简称"公司"）第三届董事会 第二十四次会议通知于2024年8月15日以书面、电子邮件的方式向全体董事发出 并送达，会议于2024年8月27日以现场结合通讯方式召开。本次会议应出席董事 7人，实际出席董事7人。会议由董事长徐旭阳先生主持，公司全体监事和高级 管理人员列席会议。本次会议的召集、召开和表决程序符合《中华人民共和国 公司法》等法律、法规、规范性文件以及《公司章程》的有关规定，所作决议 合法有效。 二、董事会会议审议情况 经与会董事认真审议，表决了以下议案： （一）审议通过《关于公司<2024年半年度报告>全文及其摘要的议案》 具体内容详见同日在巨潮资讯网（www.cninfo.com.cn）披露的《2024年半 年度报告》及《2024年半年度报告摘要》。《2024年半年度报告摘要》同时刊 登在《中国证券报 ...